Su1323 ENDOSCOPIC INJECTION SCLEROTHERAPY FOR ESOPHAGEAL VARICES EXACERBATES PORTAL HYPERTENSIVE ENTEROPATHY

Portal hypertensive enteropathy (PHE), a well-known small-bowel lesion in patients with liver cirrhosis, is associated with elevated portal vein pressure. We previously reported that aggravation of esophageal varices and portal hypertensive gastropathy predict exacerbation of PHE in patients with liver cirrhosis (Digestion 2018) and the clinical factors related to portal hypertension (portal hypertensive gastropathy, Child–Pugh class B or C, and portal vein thrombus) were significantly correlated with the presence and worsening of villous edema, which is one of the capsule endoscopy findings of PHE (Journal of gastroenterology and hepatology 2018). Endoscopic treatment for esophageal varices is often performed in patients with liver cirrhosis, and there is a report that endoscopic injection sclerotherapy (EIS) elevates portal vein pressure. However, it is still unclear how the treatment of esophageal varices actually affects PHE. We aimed to analyze and clarify the effect of treatment of esophageal varices on PHE by retrospective analysis of the capsule endoscopy findings before and after treatment in patients with liver cirrhosis.